Global CAR T Cell Therapy Market & Clinical Trials Insight 2028 Report Highlights:
- Research Methodology
- Global CAR T Cell Therapy Market Opportunity > USD 15 Billion
- Global & Regional Market Insight: Current & Market Forecast 2028
- Approved CAR T Cell Therapies Sales Forecast Till 2028
- Emerging In Vivo Induced CAR T Cell Therapies
- CAR T Cell Therapy Manufacturing Cost Analysis
- CAR T Cell Therapy Approval & Reimbursement Scenario By Country
- Patent, Price, Sales Insight On 6 Approved CAR T Cell Therapies
- Insight On More Than 600 CAR T Cell Therapies In Clinical Trials
- CAR T Cell Therapies Clinical Trials Insights by Company, Country & Phase
Download Report: https://www.kuickresearch.com/report-car-t-cell-therapy-market
Chimeric antigen receptor (CAR) T cell therapy is novel immunotherapeutic approach which involves isolation of T cells from the blood of the patient, which are then modified in a lab by the addition of a gene for a man-made receptor (chimeric antigen receptor), thus aiding in better recognizing of specific cancer cell antigens. Currently, a cocktail of CAR T cell therapy products including Yescarta, Kymriah, Tecartus, Abecma, and others have entered the global market which are indicated for the management of hematological malignancies. The encouraging response of CAR T cell therapies has propelled the further research and development activities in this domain.
The global pipeline of CAR T cell therapy is highly crowded and consists of several potential drugs. ARC-SparX developed by Arcellx is novel cell therapy platform which consist of soluble protein antigen-receptor X-linker (SparX) proteins which are specifically designed to target BCMA on myeloma cells. The company has developed novel ACLX-001 which is combination of ARC-SparX and separate dose of antigen receptor complex-T (ARC-T) cells, which gets activated only when engaged with a SparX protein that has bound to a myeloma cell. Based on the promising phase-I clinical trial investigating CART-ddBCMA, US FDA has cleared investigational new drug application for ACLX-001 in April 2021. The company recently announced that it has initiated phase-I trial evaluating ACLX-001 in patients with relapsed/refractory multiple myeloma (rrMM).
The landscape of clinical CAR T-cell immunotherapy continues to evolve rapidly. The advancement in gene-editing technology has further led to development of next generation CAR T-cells which have enhanced anti-tumor properties. Researchers have introduced multispecific CAR T-cells which have the ability to target two or more tumor associated antigens. Further, bispecific T cell engager CAR T-cells has also been developed by using special linker which has the ability to activate and recruit bystander T-cells. The targeting multiple antigens allow these CAR T-cells to maintain their cytotoxicity, enhanced specificity, and mitigate antigen escape.
Although CAR T cell therapy has demonstrated encouraging response, the market is restricted by its complex manufacturing process. Recently researchers have utilized the CliniMax prodigy by Miltenyi to simply the manufacturing process which is currently in phase-I clinical trial. The novel prodigy is self-contained, closed, and automated device which minimizes the involvement of human across various steps of manufacturing. Overall, this method helps in minimizing utilization of human resources and risks of cell contamination. The novel study has developed CD19 directed CAR T cell product with an idea to reduce the overall process to less as 2 weeks or even under. In addition, Umoja has developed UB-VV100 which is a third generation; self-activating, replication-incompetent lentivirus designed for direct injection into patients to target T cells and delivers a payload consisting of a 2nd gen anti-CD19 CAR and a rapamycin-activated cytokine receptor (RACR) system for the treatment of B cell malignancies.
As per report findings, the global CAR T cell therapy market is expected to surpass US$ 15 Billion by 2028. The huge success of CAR T cell therapy products in the market is driving the growth of market. In addition, the robust clinical pipeline of drugs which are expected to gain entry into the market during the forecast period will also drive the growth of market. Further, favorable government policies to boost the research and development in this segment are also propelling the growth of market. The key players in the market include Merck, Johnson & Johnson, Novartis, Pfizer, Bluebird Bio, Sangamo Therapeutics, and others which actively indulge in developing novel CAR T cell therapy product for the management of cancers. These companies have also adopted strategic alliances to maintain their position in the global market.
For More Information Related To Report Contact: